Entresto is a combination of a first-in-class neprilysin inhibitor and an angiotensin receptor blocker indicated for the treatment of heart failure with reduced ejection fraction.
Oluchi Juliet Emelogu, PharmD Candidate
Advertisement
Articles by Oluchi Juliet Emelogu, PharmD Candidate
Advertisement
Latest Updated Articles
EntrestoPublished: November 12th 2015 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
Modern Therapies Challenge Radiation’s Role in Early Breast Cancer Survival
3
Gedatolisib Triplet Shows Significant PFS Benefit in HR+/HER2– Breast Cancer
4
FDA Grants Orphan Drug Status to Immunotherapy for Acute Myeloid Leukemia Treatment
5
